Danish laboratory H. LUNDBECK A/S (turnover DDK 4.2 billion last year with 3,000 employed) has concluded with Belgian SOLVAY PHARMACEUTICALS a cooperation agreement for the development and marketing of an atypical antiseptic molecule for the treatment of schizophrenia.